FDA approves BioMarin's genetic disease drug

06/2/2005 | CNNMoney

The FDA has approved BioMarin Pharmaceutical's drug Naglazyme for treatment of MPS VI, a genetic disease caused by an enzyme deficiency. FDA also granted the drug orphan status, giving it seven years of market exclusivity.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA